An open-label, concentration controlled, randomized, 12 month study of Prograf [tacrolimus] + Rapamune [sirolimus] + cor [corticosteroids]

Trial Profile

An open-label, concentration controlled, randomized, 12 month study of Prograf [tacrolimus] + Rapamune [sirolimus] + cor [corticosteroids]

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Aug 2009

At a glance

  • Drugs Corticosteroids; Sirolimus; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Sponsors Wyeth; Wyeth Pharmaceuticals
  • Most Recent Events

    • 25 Aug 2009 Actual patient number (484) added as reported by ClinicalTrials.gov.
    • 25 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Aug 2009 Actual end date (Jul 2005) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top